Dovitinib

Summary

Dovitinib (CHEMBL522892) is a phase-3 clinical-stage small molecule targeting EGFR, INSR, and PDGFRA; indicated across 26 conditions including renal cell carcinoma and clear cell renal carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 12 (EGFR, INSR, PDGFRA…)
• Indications: 26 conditions
• Clinical trials: 34
• Chemistry: 392.4 Da · C21H21FN6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL522892
Name	Dovitinib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135398510
Molecular formula	C21H21FN6O
Molecular weight	392.4
InChIKey	PIQCTGMSNWUMAF-UHFFFAOYSA-N

SMILES: CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N

IUPAC name: 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one

Also known as: CHIR-258, Dovitinib, GFKI-258, NVP-TKI258, Tki-258, TKI-258, CHIR-258/TKI-258, SID103904684, SID137275871, DOVITINIB, DOVITINIB (TKI-258, CHIR-258), Dovitinib (TKI-258; CHIR-258)

Parent form; salt/anhydrous children: CHEMBL4297063, CHEMBL5570498

Patent coverage: 1,940 distinct patent families (4,944 SureChEMBL compound mentions), from 7 matched compound structure(s). One matched structure accounts for 4,067 (82%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Inhibition	5.7	17.5%	P00533
INSR	Insulin receptor	Inhibition	5.7	0.8%	P06213
PDGFRA	platelet derived growth factor receptor alpha	Inhibition	6.68	6.2%	P16234
PDGFRB	platelet derived growth factor receptor beta	Inhibition	8.3	2.3%	P09619
KIT	KIT proto-oncogene, receptor tyrosine kinase	Inhibition	8.7	0.5%	P10721
CSF1R	colony stimulating factor 1 receptor	Inhibition	8.52	0%	P07333
FLT3	fms related receptor tyrosine kinase 3	Inhibition	9	0.9%	P36888
FGFR1	fibroblast growth factor receptor 1	Inhibition	8.1	11.5%	P11362
FGFR3	fibroblast growth factor receptor 3	Inhibition	8.52	0.5%	P22607
FLT1	fms related receptor tyrosine kinase 1	Inhibition	8.52	0.1%	P17948
KDR	kinase insert domain receptor	Inhibition		1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	8.52	0.2%	P35916

Broader ChEMBL bioactivity targets: 210 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Rhodopsin kinase GRK7, Serine/threonine-protein kinase 38, STE20/SPS1-related proline-alanine-rich protein kinase, Mitogen-activated protein kinase kinase kinase 13, Microtubule-associated serine/threonine-protein kinase 1, Serine/threonine-protein kinase SBK1, Hormonally up-regulated neu tumor-associated kinase, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor.

Bioactivity

ChEMBL activities: 533 potent at pChembl ≥ 5 of 536 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FLT3	9.52	Kd	0.3	nM	CHEMBL_ACT_17903640
FLT3	9.19	Kd	0.64	nM	CHEMBL_ACT_2907383
FLT3	9.19	Kd	0.64	nM	CHEMBL_ACT_7591693
CAMK1G	9	Kd	1	nM	CHEMBL_ACT_17886447
PDGFRB	9	IC50	1	nM	CHEMBL_ACT_17979951
KIT	9	IC50	1	nM	CHEMBL_ACT_17979952
FLT3	9	IC50	1	nM	CHEMBL_ACT_17979953
CSF1R	9	IC50	1	nM	CHEMBL_ACT_17979967
KIT	8.96	IC50	1.1	nM	CHEMBL_ACT_13370872
FLT3	8.96	Kd	1.1	nM	CHEMBL_ACT_7591697
YES1	8.85	IC50	1.4	nM	CHEMBL_ACT_13395969
KIT	8.8	Kd	1.6	nM	CHEMBL_ACT_7590016
TNIK	8.7	IC50	2	nM	CHEMBL_ACT_16433822
P11799	8.7	Kd	2	nM	CHEMBL_ACT_2901473
MYLK3	8.7	Kd	2	nM	CHEMBL_ACT_7591947
FLT4	8.6	IC50	2.51	nM	CHEMBL_ACT_13418834
FLT1	8.52	IC50	3	nM	CHEMBL_ACT_2250295
FLT4	8.52	IC50	3	nM	CHEMBL_ACT_2250296
FGFR3	8.52	IC50	3	nM	CHEMBL_ACT_2250297
KIT	8.52	IC50	3	nM	CHEMBL_ACT_2250298
CSF1R	8.52	IC50	3	nM	CHEMBL_ACT_2250299
FLT3	8.52	IC50	3	nM	CHEMBL_ACT_2250300
KIT	8.51	Kd	3.1	nM	CHEMBL_ACT_2896989
KIT	8.51	Kd	3.1	nM	CHEMBL_ACT_7590019
FLT3	8.5	Ki	3.16	nM	CHEMBL_ACT_9599368
FLT3	8.44	Kd	3.6	nM	CHEMBL_ACT_2890811
FLT3	8.44	Kd	3.6	nM	CHEMBL_ACT_7591696
PDGFRB	8.42	Kd	3.8	nM	CHEMBL_ACT_2899069
PDGFRB	8.42	Kd	3.8	nM	CHEMBL_ACT_7591631
FLT3	8.32	Kd	4.8	nM	CHEMBL_ACT_2890849

Target pathways

Aggregated over 12 target gene(s): EGFR, INSR, PDGFRA, PDGFRB, KIT, CSF1R, FLT3, FGFR1, FGFR3, FLT1, KDR, FLT4.

Top Reactome pathways

146 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	8	EGFR, FGFR1, FGFR3, FLT3, INSR, KIT, PDGFRA, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	8	EGFR, FGFR1, FGFR3, FLT3, INSR, KIT, PDGFRA, PDGFRB
Constitutive Signaling by Aberrant PI3K in Cancer	7	EGFR, FGFR1, FGFR3, FLT3, KIT, PDGFRA, PDGFRB
RAF/MAP kinase cascade	7	EGFR, FGFR1, FGFR3, FLT3, KIT, PDGFRA, PDGFRB
PI3K Cascade	3	FGFR1, FGFR3, FLT3
VEGF binds to VEGFR leading to receptor dimerization	3	FLT1, FLT4, KDR
Signal Transduction	2	INSR, KIT
Downstream signal transduction	2	PDGFRA, PDGFRB
Signaling by PDGF	2	PDGFRA, PDGFRB
Neuropilin interactions with VEGF and VEGFR	2	FLT1, KDR
Negative regulation of the PI3K/AKT network	2	INSR, KIT
Signal transduction by L1	2	EGFR, FGFR1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	2	EGFR, KIT
Intracellular signaling by second messengers	2	INSR, KIT
Signaling by Receptor Tyrosine Kinases	2	INSR, KIT
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
Signaling by ERBB2	1	EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
SHC1 events in ERBB2 signaling	1	EGFR
PLCG1 events in ERBB2 signaling	1	EGFR
Developmental Biology	1	KIT
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT
Disease	1	KIT
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR

Dominant GO biological processes

GO term	Targets
positive regulation of cell population proliferation	12
protein phosphorylation	12
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	11
cell surface receptor protein tyrosine kinase signaling pathway	10
protein autophosphorylation	10
positive regulation of cell migration	9
positive regulation of MAPK cascade	9
cell migration	9
peptidyl-tyrosine phosphorylation	8
positive regulation of ERK1 and ERK2 cascade	7
cell population proliferation	5
angiogenesis	5
positive regulation of protein phosphorylation	4
signal transduction	4
negative regulation of apoptotic process	4

Indications & clinical

Indications

26 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
clear cell renal carcinoma	3	MONDO:0005005	EFO:0000349
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
adenoid cystic carcinoma	2	MONDO:0004971	EFO:0000231
neoplasm	2	MONDO:0005070	EFO:0000616
malignant pleural mesothelioma	2	MONDO:0005112	EFO:0000770
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
glioblastoma	2	MONDO:0018177	EFO:0000519
gliosarcoma	2	MONDO:0016681	EFO:1001465
adrenal cortex carcinoma	2	MONDO:0006639	EFO:1000796
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
breast neoplasm	2	MONDO:0021100	MONDO:0007254
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
von Hippel-Lindau disease	2	MONDO:0008667	MONDO:0008667
gastrointestinal stromal tumor	2	MONDO:0011719	MONDO:0011719
adrenal gland pheochromocytoma	2	MONDO:0004974	EFO:0000239
brain neoplasm	2	MONDO:0021211	EFO:0003833
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
melanoma	1	MONDO:0005105	EFO:0000756

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE2	22
PHASE1	8
PHASE1/PHASE2	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01223027	PHASE3	COMPLETED	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
NCT02116803	PHASE2/PHASE3	COMPLETED	An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
NCT01232296	PHASE2	COMPLETED	A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
NCT01262027	PHASE2	COMPLETED	TKI258 for Metastatic Inflammatory Breast Cancer Patients
NCT01266070	PHASE2	TERMINATED	TKI 258 in Von Hippel-Lindau Syndrome (VHL)
NCT01440959	PHASE2	COMPLETED	Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
NCT01478373	PHASE2	COMPLETED	Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
NCT01484041	PHASE1/PHASE2	TERMINATED	Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
NCT01514526	PHASE2	COMPLETED	Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
NCT01524692	PHASE2	COMPLETED	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
NCT01528345	PHASE2	TERMINATED	Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
NCT01635907	PHASE2	COMPLETED	Dovitinib in Neuroendocrine Tumors
NCT01676714	PHASE2	COMPLETED	Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
NCT01678105	PHASE2	COMPLETED	A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
NCT01719549	PHASE2	COMPLETED	Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1
NCT01732107	PHASE2	TERMINATED	Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
NCT01753713	PHASE2	COMPLETED	Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT01769547	PHASE2	TERMINATED	A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
NCT01791387	PHASE2	UNKNOWN	1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
NCT01831726	PHASE2	COMPLETED	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
NCT01861197	PHASE2	UNKNOWN	Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
NCT01888965	PHASE2	TERMINATED	Maintenance Dovitinib for Colorectal and Pancreas Cancer
NCT01921673	PHASE1/PHASE2	COMPLETED	Dovitinib Plus Docetaxel in Gastric Cancer
NCT01964144	PHASE2	COMPLETED	An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
NCT01994590	PHASE2	TERMINATED	Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NCT02065323	PHASE2	WITHDRAWN	A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
NCT01270906	PHASE1	TERMINATED	Safety of CHIR-258 (TKI258) in Advanced Solid Tumors
NCT01443481	PHASE1	COMPLETED	Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
NCT01548924	PHASE1	TERMINATED	Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
NCT01680796	PHASE1	WITHDRAWN	Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT01700270	PHASE1	COMPLETED	Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
NCT01714765	PHASE1	COMPLETED	Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
NCT01972750	PHASE1	UNKNOWN	Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
NCT05571969	PHASE1	SUSPENDED	Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

341 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
FEDRATINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
SORAFENIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
SUNITINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
LESTAURTINIB	ChEMBL	Phase 3	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
LINIFANIB	ChEMBL	Phase 3	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
CENISERTIB	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
FORETINIB	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
ILORASERTIB	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
R-406	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
SU-014813	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
TOZASERTIB	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA
AXITINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
NINTEDANIB	ChEMBL	Phase 4 (approved)	CSF1R, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
VANDETANIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
CEDIRANIB	ChEMBL	Phase 3	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
TANDUTINIB	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FGFR1, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB
DASATINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
PONATINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
BRIVANIB	ChEMBL	Phase 3	CSF1R, EGFR, FGFR1, FGFR3, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
MOTESANIB	ChEMBL	Phase 3	CSF1R, EGFR, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SEMAXANIB	ChEMBL	Phase 3	CSF1R, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
DORAMAPIMOD	ChEMBL	Phase 2	CSF1R, EGFR, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
OSI-632	ChEMBL	Phase 2	EGFR, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, PDGFRA, PDGFRB
Idelalisib	PubChem	Approved	CSF1R, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KIT, PDGFRA, PDGFRB
BRIGATINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FGFR1, FGFR3, FLT3, FLT4, INSR, KDR, KIT
ENTRECTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA
DEFOSBARASERTIB	ChEMBL	Phase 2	CSF1R, EGFR, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
RAF-265	ChEMBL	Phase 2	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
REBASTINIB	ChEMBL	Phase 2	CSF1R, FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
LENVATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR3, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
QUIZARTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
TIVOZANIB	ChEMBL	Phase 4 (approved)	FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
VATALANIB	ChEMBL	Phase 3	CSF1R, EGFR, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, EGFR, FLT3, KDR, KIT, PDGFRA, PDGFRB
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR, FGFR1, FLT1, FLT3, FLT4, KDR, KIT
CERITINIB	ChEMBL	Phase 4 (approved)	EGFR, FGFR3, FLT3, INSR, KDR, KIT, PDGFRA
NINTEDANIB ESYLATE	ChEMBL	Phase 4 (approved)	FGFR1, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
CANERTINIB	ChEMBL	Phase 3	EGFR, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
AT-9283	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, PDGFRA
CEP-11981	ChEMBL	Phase 2	CSF1R, FGFR1, FGFR3, FLT1, FLT3, KDR, PDGFRA
CEP-32496	ChEMBL	Phase 2	CSF1R, EGFR, FLT1, FLT3, KDR, KIT, PDGFRB
MK-2461	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, FLT3, FLT4, KDR, PDGFRB
BOSUTINIB	ChEMBL	Phase 4 (approved)	CSF1R, EGFR, FLT3, KIT, PDGFRA, PDGFRB
BARASERTIB	ChEMBL	Phase 3	EGFR, FLT3, KDR, KIT, PDGFRA, PDGFRB
SARACATINIB	ChEMBL	Phase 3	EGFR, FLT3, KDR, KIT, PDGFRA, PDGFRB
ENMD-2076	ChEMBL	Phase 2	CSF1R, FGFR1, FLT3, KDR, KIT, PDGFRA
LUCITANIB	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, FLT4, KDR, PDGFRB
MILCICLIB	ChEMBL	Phase 2	EGFR, FGFR1, FLT3, FLT4, KIT, PDGFRB
Binimetinib	PubChem	Approved	EGFR, FGFR1, FLT3, INSR, KDR, PDGFRB
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, FGFR1, FLT3, INSR, PDGFRB